The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.
The settlement will provide $115 million in cash and $35 million in opioid addiction treatment medication to resolve claims brought by states and local communities against Hikma.
Alto Neuroscience and Fractyl Health provided further momentum to the recent spate of biotech initial public offerings, with both companies going public on Friday morning in respective $128 million and $110 million IPOs.
The Chicago-based drugmaker has been counting on revenues from its newer immunology medicines to help make up for declining sales of its blockbuster arthritis drug Humira.
The company’s new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid outperformed Wall Street forecasts.
ReutersRegeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker’s preliminary estimates target.
Recent headlines are sounding alarm bells over the highest jump in healthcare costs in a decade. The impact has the potential to cause disruptions across key market access channels: employers, health plans, and pharmacy benefit managers.
Abbott, the global leader in screening blood and plasma, partnered with Blood Centers of America, the largest blood supplier network in the U.S., to launch a mixed reality experience for blood donors in June 2023. Results from a pilot study reveal that mixed reality “is an innovative technology that holds promise to increase donor engagement, satisfaction, and retention,” researchers said.
The Biden administration is sending drugmakers opening offers for the U.S. Medicare program’s first ever price negotiations on Thursday, the White House said in a statement.
Despite strong sales of its blockbuster drug Dupixent, Sanofi reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.
